Tenaya Therapeutics Inc's Customers Performance

Name: Tenaya Therapeutics Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

TNYA

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


TNYA's Source of Revenues		During the corresponding time, Tenaya Therapeutics Inc sequentially revenue grew by 393.33 %. While revenue at the Tenaya Therapeutics Inc 's corporate clients • List of TNYA Customers

for the same period Tenaya Therapeutics Inc sequentially revenue grew by 393.33 %.

• List of TNYA Customers

Tenaya Therapeutics Inc's Business Units

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Tenaya Therapeutics Inc's Comment on Sales, Marketing and Customers

News about Tenaya Therapeutics Inc Contracts

Tenaya Therapeutics to Reveal Phase 1b/2 Trial Data for TN-201 Gene Therapy on December 17, 2024,

Tenaya Therapeutics, a clinical-stage biotechnology company, is poised to make a significant announcement regarding its ongoing efforts to address hypertrophic cardiomyopathy (HCM) a genetic heart condition that leads to thickening of the heart muscle and can result in serious complications. On December 17, 2024, the company will share initial data from its MyPEAK-1 Phase 1b/2 clinical trial investigating the efficacy and safety of TN-201, an innovative gene therapy specifically designed for patients with MYBPC3-associated HCM.The MyPEAK-1 trial is particularly noteworthy as it represents a critical step towards bringing novel therapies to patients afflicted with MYBPC3-associated HCM, which is one of the ...

Revamping Cardiac Care: Tenaya Therapeutics' Quest for Precision Heart Medicines

Engineering the Future of Precision Heart Medicines: Tenaya Therapeutics Continued Innovation in Capsid Engineering, Gene Editing, and ManufacturingIn the pursuit of developing innovative medicines, scientific advancements in gene and cell therapies have played a pivotal role. Tenaya Therapeutics, a leading biotechnology company, has been at the forefront of this field, showcasing their growing capabilities in capsid engineering, gene editing, and manufacturing. At the recent American Society of Gene and Cell Therapy 27th Annual Meeting, Tenaya Therapeutics presented abstracts that highlighted their continued innovation across these core competencies. These advancements not only facilitate their current pip...

TNYA's Stock Performance relative to it's Customers

TNYA's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Tenaya Therapeutics Inc	132.63	0.00	-103.12	70
SUBTOTAL	0.00	0.00	0.00	-

Sources: Tenaya Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Tenaya Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Tenaya Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.